The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia

Exclusion Criteria

• •Patient refusal;
• •Inability to sign informed consent;
• •Had other secondary FM, this is, hypothyroidism, nutritional deficiency, diabetes mellitus, connective tissue disorder;
• •Had psychiatric disorder, this is, schizophrenia and other psychotic disorder, bipolar disorder, or personality disorder;
• •Obstructive sleep apnea syndrome or a STOP-Bang score ≥ 3;
• •History of treatment with pregabalin and/or venlafaxine for any disease;
• •History of treatment with intravenous ketamine or ESK for chronic pain;
• •Presence of other painful ailments such as inflammatory rheumatic disease;
• •Uncontrolled diabetes, refractory hypertension, malignancies, narrow-angle glaucoma, hyperthyroidism, severe cardiovascular disease or any other contraindications to esketamine;
• •History of prescription drug abuse, alcoholism or illicit drug use;
• •Pregnant or lactating women;
• •Allergic to any of the study drugs.